Veranlagung für Brustkrebs: genetische Varianten und Prognose in der prospektiv randomisierten SUCCESS A-Studie

Translated title of the contribution: Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study

A. Hein, B. Rack, L. Li, A. B. Ekici, A. Reis, M. P. Lux, Julie M Cunningham, M. Rübner, B. L. Fridley, A. Schneeweiss, H. Tesch, W. Lichtenegger, T. Fehm, G. Heinrich, M. Rezai, M. W. Beckmann, W. Janni, Richard M Weinshilboum, Liewei M Wang, P. A. FaschingL. Häberle

Research output: Contribution to journalArticle

8 Scopus citations


Large-scale genotyping studies have identified over 70 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. However, knowledge regarding genetic risk factors associated with the prognosis is limited. The aim of this study was therefore to investigate the prognostic effect of nine known breast cancer risk SNPs. BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277 (CASP8), rs2981582 (FGFR2), rs13281615(8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042(2q35), rs4973768 (SLC4A7), rs6504950 (COX11). Cox proportional hazards models were used to test the SNPs' association with overall survival (OS) and progression-free survival (PFS). Additional analyses were carried out for molecular subgroups. rs3817198 in LSP1 (lymphocyte-specific protein 1) was the only SNP that significantly influenced OS (p = 0.01) and PFS (p < 0.01) in the likelihood ratio test comparing the genetic survival model with the clinical survival model. In the molecular subgroups, triple-negative patients with two minor alleles in rs3817198 had a much better prognosis relative to OS (adjusted HR 0.03; 95% CI 0.002-0.279) and PFS (HR 0.09; 95% CI 0.02-0.36) than patients with the common alleles. The same effect on PFS was shown for patients with luminal A tumors (HR 0.19; 95% CI 0.05-0.84), whereas patients with luminal B tumors had a poorer PFS with two minor alleles (HR 2.13; 95% CI 1.02-4.40). The variant in rs3817198 has a prognostic effect particularly in the subgroup of patients with triple-negative BC, suggesting a possible link with immunomodulation and BC.

Original languageGerman
Pages (from-to)651-659
Number of pages9
JournalGeburtshilfe und Frauenheilkunde
Issue number6
StatePublished - Jun 1 2017



  • breast cancer
  • LSP1
  • prognosis
  • SNP
  • TNBC

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Maternity and Midwifery

Cite this

Hein, A., Rack, B., Li, L., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Rübner, M., Fridley, B. L., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., Wang, L. M., ... Häberle, L. (2017). Veranlagung für Brustkrebs: genetische Varianten und Prognose in der prospektiv randomisierten SUCCESS A-Studie. Geburtshilfe und Frauenheilkunde, 77(6), 651-659.